ALFA Finder
20:34 IST
NSE
Earnings Call
Zim Laboratories Investor Presentation: Key Takeaways
Q2 FY27 operating income ₹1,054 Mn (+18.9% YoY), EBITDA ₹77 Mn at 7.3% margin, PAT loss ₹21 Mn. EU-GMP cost base weighs on margins.
Zim Laboratories Ltd
- Share price
- ₹134.66
- Market cap
- ₹722.6 Cr
- Revenue (annual)
- ₹374.4 Cr
- Net profit (annual)
- ₹5.84 Cr
- P/E (TTM)
- 348.8×Sector 43.8×
- Promoter holding
- 30.30%-0.06% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
14:36 IST
NSE
Financial Results
Zim Laboratories Q2 FY27 Results: Net Loss of ₹2 Cr, Loss Widens
Zim Laboratories Ltd reported revenue from operations of ₹105.4 Cr (+18.8% YoY) and a net loss of ₹2 Cr for Q2 FY27.
- Key figure
- Net loss ₹2 Cr
16:12 IST
BSE
Board Meeting Date
Zim Laboratories Board Meeting Date
Zim Laboratories has scheduled a board meeting on 4 November 2026 to consider its unaudited quarterly results for the quarter ended 30 September 2026. The trading window stays closed from 1 October to 6 November 2026.
12:50 IST
NSE
Regulatory Approval
Zim Laboratories Regulatory Approval
Zim Laboratories received TGA GMP certification from Australia's Therapeutic Goods Administration for its Nagpur manufacturing facility. The certification covers various dosage forms and is valid until June 2028.
- From
- Therapeutic Goods Administration (TGA), Australia